What is the primary purpose of these amendments to the warrant agreements?

The primary purpose of these amendments is to reduce the number of outstanding warrants held by Credit Suisse and Goldman Sachs. These warrants were originally issued in connection with Regeneron's 2011 convertible senior notes and related hedging transactions. By reducing the warrants, Regeneron is managing its obligations related to these financial instruments.

How much is Regeneron paying to reduce these warrants?

Regeneron paid $50.8 million to Credit Suisse for the reduction of warrants. For the reduction with Goldman Sachs, the aggregate amount payable will not exceed $148.5 million, with the final amount determined by the market price of Regeneron's stock during a specified period.

What is the potential impact on Regeneron's financials?

These transactions represent a significant cash outflow for Regeneron, totaling up to $199.3 million ($50.8 million to Credit Suisse and a maximum of $148.5 million to Goldman Sachs). This reduces the company's outstanding debt-related financial instruments and associated future obligations, potentially simplifying its capital structure and reducing dilution risk from warrants.

When will the reduction of warrants with Goldman Sachs be finalized?

The reduction in warrants with Goldman Sachs will be determined based on their hedging activities during the transaction period, which starts on November 26, 2014, and ends no later than February 12, 2015. The payment will be due shortly after the end of this period.

REGN 8-K: Material Agreements

Summary

Regeneron Pharmaceuticals, Inc. has filed an 8-K report detailing material definitive agreements related to its outstanding warrants. The company has entered into a Third Amendment to its Warrant Agreement with Credit Suisse Capital LLC, reducing the number of outstanding warrants by 24.2% (164,409 warrants) for a payment of $50.8 million. This amendment impacts warrants issued in 2011 in connection with the company's 1.875% convertible senior notes. Furthermore, Regeneron has entered into a Second Amendment to its Warrant Agreement with Goldman, Sachs & Co. This agreement allows for a reduction of up to 49.2% (493,229 warrants) in outstanding warrants. The aggregate payment by Regeneron will not exceed $148.5 million, and the final amount will be determined by the volume-weighted average price of shares purchased by Goldman Sachs to close out its hedging positions during a specified transaction period ending in February 2015. These actions suggest a proactive approach by Regeneron to manage its convertible note-related hedging obligations.

Key Highlights

1Regeneron entered into a Third Amendment to its Warrant Agreement with Credit Suisse Capital LLC on November 24, 2014.
2The Third Amendment reduces the number of outstanding warrants held by Credit Suisse by 164,409 (24.2%) for a payment of $50.8 million.
3Regeneron entered into a Second Amendment to its Warrant Agreement with Goldman, Sachs & Co. on November 25, 2014.
4The Second Amendment allows for a reduction of up to 493,229 (48.9%) warrants held by Goldman Sachs.
5The payment to Goldman Sachs will not exceed $148.5 million and will be based on the volume-weighted average price of shares purchased to close out hedging positions.
6The reduction in warrants for Goldman Sachs is tied to a transaction period from November 26, 2014, to February 12, 2015.
7These amendments relate to warrants originally issued in 2011 in connection with the company's 1.875% convertible senior notes.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Nov 26, 2014)

Summary

Key Highlights

Frequently Asked Questions